ArticleFrontiers in pharmacology2022

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp.

Tingting Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.